Tag: Charl van Zyl

UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

pharmanewsdaily- July 29, 2020

Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer's Disease drug candidate (AD drug candidate) ... Read More